DeepLife

Executive Summary

DeepLife is a French biotech startup founded in 2019 that applies deep learning to multi-omics data to create digital twins of cells. By modeling cellular behavior, the company aims to identify molecular triggers that can revert diseased cells to a healthy state, thereby accelerating drug discovery. Its platform integrates AI, systems engineering, and multi-dimensional biological data to simulate disease progression and drug responses in silico. This approach reduces the need for costly and time-consuming wet-lab experiments, potentially shortening the drug development timeline. DeepLife is poised to address high unmet needs in complex diseases such as cancer, neurodegeneration, and rare disorders. The company operates at the intersection of AI and biology, leveraging advances in machine learning to interpret vast datasets generated by modern genomics, proteomics, and metabolomics technologies. Its digital twin technology offers a unique value proposition: the ability to test thousands of molecular interventions rapidly and predict their effects on cellular states. Since its inception, DeepLife has positioned itself as a key player in the AI-driven drug discovery space, with a focus on building rich, dynamic models that capture the complexity of human biology. Although still in early stages, the company benefits from a strong scientific foundation and a clear vision to transform how drugs are discovered and developed. With a conviction score of 75, DeepLife represents a compelling opportunity in the precision medicine and computational biology landscape.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round70% success
• Q3 2026Pharmaceutical Partnership60% success
• Q2 2027Proof-of-Concept Study Results80% success